These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36803618)

  • 1. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease?
    Lenka A; Jankovic J
    Expert Rev Neurother; 2023 Feb; 23(2):107-122. PubMed ID: 36803618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.
    McFarthing K; Buff S; Rafaloff G; Pitzer K; Fiske B; Navangul A; Beissert K; Pilcicka A; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2024; 14(5):899-912. PubMed ID: 39031388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.
    Evans JR; Barker RA
    Expert Opin Pharmacother; 2011 Jun; 12(8):1249-58. PubMed ID: 21345151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.
    McFarthing K; Rafaloff G; Baptista MAS; Wyse RK; Stott SRW
    J Parkinsons Dis; 2021; 11(3):891-903. PubMed ID: 34151864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.
    McFarthing K; Rafaloff G; Baptista M; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2022; 12(4):1073-1082. PubMed ID: 35527571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing the First Trials for Parkinson's Prevention.
    Crotty GF; Ayer SJ; Schwarzschild MA
    J Parkinsons Dis; 2024; 14(s2):S381-S393. PubMed ID: 39302381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
    McFarthing K; Buff S; Rafaloff G; Dominey T; Wyse RK; Stott SRW
    J Parkinsons Dis; 2020; 10(3):757-774. PubMed ID: 32741777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.
    McFarthing K; Buff S; Rafaloff G; Fiske B; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2023; 13(4):427-439. PubMed ID: 37302040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
    Löhle M; Reichmann H
    J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status and future directions of clinical trials in Parkinson's disease.
    Söderbom G
    Int Rev Neurobiol; 2020; 154():153-188. PubMed ID: 32739003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection in Parkinson's disease: myth or reality?
    Voss T; Ravina B
    Curr Neurol Neurosci Rep; 2008 Jul; 8(4):304-9. PubMed ID: 18590614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.
    Gonzalez-Robles C; Weil RS; van Wamelen D; Bartlett M; Burnell M; Clarke CS; Hu MT; Huxford B; Jha A; Lambert C; Lawton M; Mills G; Noyce A; Piccini P; Pushparatnam K; Rochester L; Siu C; Williams-Gray CH; Zeissler ML; Zetterberg H; Carroll CB; Foltynie T; Schrag A;
    J Parkinsons Dis; 2023; 13(6):1011-1033. PubMed ID: 37545260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and emerging medical therapies in Parkinson's disease.
    Lotia M; Jankovic J
    Expert Opin Pharmacother; 2016; 17(7):895-909. PubMed ID: 26830844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial designs used to study neuroprotective therapy in Parkinson's disease.
    Lang AE; Melamed E; Poewe W; Rascol O
    Mov Disord; 2013 Jan; 28(1):86-95. PubMed ID: 22927060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.